We have located links that may give you full text access.
Journal Article
Review
Targeting NCA-95 and other granulocyte antigens and receptors with radiolabeled monoclonal antibodies (Mabs).
During the last decade considerable effort has been made in the research for in vivo techniques of labeling neutrophils with peptides, labeled cytokines and (99m)Tc-labeled antigranulocyte monoclonal antibodies (AG-Mabs). In general the advantage of in vivo labeling is the simplicity of this approach compared with in vivo techniques. Three of these AG-Mabs have been evaluated in clinical studies: Besilesomab (Scintimun®), Sulesomab (Leucoscan®) and Fanolesomab (Leu-Tech®). White blood cells (WBCs) radiolabeled with AG-Mabs do not show the same behaviour as in vivo labeled white blood cells. Especially (99m)Tc-Sulesomab and (99m)Tc-Besilesomab image infectious foci mainly by non-specific extravasation with secondary binding to postmigratory leukocytes already present at the site of infection.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app